Various systemic inflammation indices have emerged as prognostic markers for renal cell carcinoma (RCC); however, these indices have not been comprehensively integrated.
In this study, we propose a novel systemic inflammation indice, the platelet-neutrophil-monocyte-lymphocyte ratio (PNMLR), aimed at more accurately assessing survival outcomes of patients with non-metastatic RCC.
